NASDAQ:GNCA Genocea Biosciences (GNCA) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free GNCA Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume83,499 shsMarket Capitalization$6,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial Media Get Genocea Biosciences alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Genocea Biosciences Stock (NASDAQ:GNCA)Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.Read More Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him GNCA Stock News HeadlinesApril 16, 2024 | americanbankingnews.comGenocea Biosciences (NASDAQ:GNCA) Now Covered by Analysts at StockNews.comJanuary 5, 2024 | morningstar.comGenocea Biosciences Inc GNCAQApril 23, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.January 27, 2023 | seekingalpha.comGNCAQ Genocea Biosciences, Inc.August 31, 2022 | thestreet.com3 Health Care Stocks Under $10 to Trade for BreakoutsAugust 9, 2022 | uk.finance.yahoo.comGenocea Biosciences, Inc. (GNCA)May 27, 2022 | seekingalpha.comGRPN, GNCA and LAB among mid-day moversMay 25, 2022 | finance.yahoo.comGenocea Biosciences to shut downApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.May 24, 2022 | finance.yahoo.comGenocea Closes Shop, Delists From NASDAQMay 24, 2022 | finance.yahoo.comThree weeks after layoffs, Genocea shuts down entirelyMay 24, 2022 | seekingalpha.comGenocea stock crashes 64% on winding down of operations, Nasdaq delistingMay 24, 2022 | finance.yahoo.comGenocea Announces Wind Down of Operations and Delisting From NASDAQMay 2, 2022 | finance.yahoo.comGenocea cuts two-thirds of staff, explores a saleApril 29, 2022 | seekingalpha.comGenocea stock plunges on cutting workforce by 65% and exploring sale or merger alternatives; Stifel cuts PT to $0.16April 28, 2022 | finance.yahoo.comGenocea Initiates Restructuring and Announces Plan to Explore Strategic AlternativesApril 11, 2022 | finance.yahoo.comImplied Volatility Surging for Genocea (GNCA) Stock OptionsApril 8, 2022 | uk.investing.comGenocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor PatientsApril 8, 2022 | finance.yahoo.comGenocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022April 4, 2022 | finance.yahoo.comGenocea Biosciences to Host Investor WebinarMarch 14, 2022 | finance.yahoo.comGenocea to Present at the 32nd Annual Oppenheimer Healthcare ConferenceMarch 10, 2022 | seekingalpha.comGenocea Biosciences GAAP EPS of -$0.19 misses by $0.01March 10, 2022 | apnews.comGenocea Biosciences: Q4 Earnings SnapshotMarch 10, 2022 | finance.yahoo.comGenocea Provides Fourth Quarter 2021 Corporate UpdateMarch 9, 2022 | seekingalpha.comGenocea Biosciences Q4 2021 Earnings PreviewMarch 9, 2022 | benzinga.comGenocea Biosciences Earnings PreviewMarch 8, 2022 | finance.yahoo.comGenocea to Present Clinical and Preclinical Data at AACR Annual MeetingSee More Headlines Receive GNCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/27/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GNCA CUSIPN/A CIK1457612 Webwww.genocea.com Phone(617) 876-8191Fax617-876-8192Employees74Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,200,000.00 Net MarginsN/A Pretax Margin-1,946.15% Return on Equity-182.88% Return on Assets-62.76% Debt Debt-to-Equity Ratio0.24 Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual Sales$1.91 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / BookN/AMiscellaneous Outstanding Shares58,730,000Free Float57,788,000Market Cap$6,000.00 OptionableNot Optionable Beta1.61 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. William D. Clark M.B.A. (Age 53)Pres, CEO & Director Comp: $837.42kDr. Jessica Baker Flechtner Ph.D. (Age 50)Chief Scientific Officer Comp: $585.18kMs. Diantha Duvall CPA (Age 50)M.B.A., CFO & Sec. Key CompetitorsKaleido BiosciencesNASDAQ:KLDOHTG Molecular DiagnosticsNASDAQ:HTGMQViveve MedicalNASDAQ:VIVEAllied Healthcare ProductsNASDAQ:AHPINVN LiquidationNASDAQ:NOVNQView All Competitors GNCA Stock Analysis - Frequently Asked Questions How were Genocea Biosciences' earnings last quarter? Genocea Biosciences, Inc. (NASDAQ:GNCA) announced its quarterly earnings data on Wednesday, October, 27th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.15. The biotechnology company earned $1.64 million during the quarter. During the same quarter in the prior year, the company earned ($0.26) earnings per share. What is William Clark's approval rating as Genocea Biosciences' CEO? 5 employees have rated Genocea Biosciences Chief Executive Officer William Clark on Glassdoor.com. William Clark has an approval rating of 82% among the company's employees. What other stocks do shareholders of Genocea Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO). How do I buy shares of Genocea Biosciences? Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GNCA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
